In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
Authors:
Open Access
- 15 July 2015
- journal article
- opinion
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (3) , e1055061
Abstract
Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is a potent and promising treatment option with the potential to harness the intrinsic antitumor power of the immune system and provide long-term immunity against cancer.Keywords
This publication has 10 references indexed in Scilit:
- Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical TrialClinical Cancer Research, 2015
- Adoptive cell transfer as personalized immunotherapy for human cancerScience, 2015
- HER2 and Breast Cancer Stem Cells: More than Meets the EyeCancer Research, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathwayJournal of Translational Medicine, 2013
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated StimulationClinical Cancer Research, 2006
- Anti-CD3 × Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancer–Bearing Severe Combined Immunodeficient Beige MiceClinical Prostate Cancer, 2004
- Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu + TumorsJournal of Hematotherapy & Stem Cell Research, 2001